{"id":"e2ad17036090","type":"article","url":"https://hartvaat.nl/2017/02/01/vernakalant-versus-ibutilide-voor-sinusritme-bij-recent-onset-af-gerandomiseerde/","title":"Vernakalant versus ibutilide voor sinusritme bij recent-onset AF: gerandomiseerde trial","title_en":"Vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation: a randomized controlled trial at the emergency department.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euw052","source_url":"https://doi.org/10.1093/europace/euw052","authors":["Alexander Simon","Jan Niederdoeckl","Ekaterini Skyllouriotis","Nikola Schuetz","Harald Herkner","Christoph Weiser","Anton N Laggner","Hans Domanovits","Alexander O Spiel"],"significance":6,"published":"2017-02-01","source_date":"2017-02-01","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ecg-herkenning-af/","https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"This randomized trial showed that vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation, providing head-to-head comparative data for intravenous cardioversion agents.","created":"2026-07-03T10:26:32Z","updated":"2026-07-03T13:25:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Gerandomiseerde trial die aantoont dat vernakalant superieur is aan ibutilide voor het bereiken van sinusritme bij patiënten met recent-onset AF.","abstract_original":"AIMS: Ibutilide is a rapid-acting antiarrhythmic drug with worldwide use for conversion of recent-onset atrial fibrillation. Vernakalant, approved in the EU in 2010, is likewise used intravenously, with proven efficacy and safety compared with placebo and amiodarone in randomized clinical trials. The aim of our study was to compare the time to conversion and the conversion rate within 90 min in patients with recent-onset atrial fibrillation treated with vernakalant or ibutilide. METHODS AND RESULTS: A randomized controlled trial registered at clinicaltrials.gov (NCT01447862) was performed in 100 patients with recent-onset atrial fibrillation treated at the emergency department of a tertiary care hospital. Patients received up to two short infusions of vernakalant (n = 49; 3 mg/kg followed by 2 mg/kg if necessary) or ibutilide (n = 51; 1 mg followed by another 1 mg if necessary) according to the manufacturer's instructions. Clinical and laboratory variables, adverse events, conversion rates, and time to conversion were recorded. Time to conversion of AF to sinus rhythm was significantly shorter in the vernakalant group compared with the ibutilide group (median time: 10 vs. 26 min, P = 0.01), and likewise the conversion success within 90 min was significantly higher in the vernakalant group (69 vs. 43%, log-rank P = 0.002). No serious adverse events occurred. CONCLUSION: Vernakalant was superior to ibutilide in converting recent-onset atrial fibrillation to sinus rhythm in the emergency department setting."}